The company said that the new facility will allow its global vaccines biz to expand its supply of VaxigripTetra, a quadrivalent flu vaccine, to up to 70 countries in six continents.
“Influenza continues to be a major public health problem around the world, causing serious complications, hospitalizations and deaths, mostly for certain high-risk individuals,” David Loew, Sanofi’s EVP and head of Sanofi Pasteur, said in prepared remarks.
“As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur’s ability to tackle this underestimated health challenge.”
Sanofi Pasteur is the only vaccine producer in France, according to the pharma giant. The company plans to finish the facility’s expansion by 2021 and said it will start producing vaccines by 2022.
“This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions,” Philippe Luscan, EVP of the company’s global industrial affairs unit, added. “Our investment underlines Sanofi’s intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”